Tagged with M

USA David H. Crean, Ph.D., is a San Diego-based venture capitalist and strategic advisor with over 30 years of experience in life sciences and healthcare. Drawing on a deep personal connection to Alzheimer’s disease as well as decades of experience as a scientist and investor, Crean casts his eye over the…

Saudi Arabia Michio Kondo, Fujifilm’s MEA managing director, discusses the company’s remarkable growth in the Middle East and Africa since 2022, highlighting key developments such as the acquisition of Hitachi’s imaging division in 2021, which expanded their product portfolio to include MRI, CT, and ultrasound equipment. Fujifilm has also strengthened its presence…

Saudi Arabia Sue Donoghue, with 29 years of experience in logistics, has been with DHL for 19 years and helped establish DHL Global Forwarding in Saudi Arabia in 2020, growing the team from 4 to 250 people. As Vice Chair of the European Chamber of Commerce in Saudi Arabia, Donoghue aims to…

Saudi Arabia Dr Adel AlMarshad, MD MPH serves as General Supervisor for the Health and Biotechnology Sectors at the Royal Commission for Riyadh City (RCRC) as well as Executive Director of Riyadh Megaprojects in Health, Biotechnology, and Medical Tourism. Dr. El Marshad discusses the RCRC’s pivotal role in transforming Riyadh into a global…

Germany Rainer Westermann, chairman of the Life Sciences Acceleration Alliance e.V. looks out over the choppy waters for life sciences venture capitalists in Europe over 2025. Three key initiatives stand to reshape the continent’s investment climate, but broader geopolitical winds – especially those now emanating from the White House – could…

Europe Dr Carolyn H. Rogers, Rushikesh S. Dasoondi and Dr Michael A. Roberts from UK and European intellectual property law firm Reddie & Grose LLP examine the intersection of personalised medicine and rare diseases and its implications for IP law.   Personalised medicine, also referred to as precision medicine, is an…

Europe Will a new ‘Critical Medicines Act’ go far enough to ensure Europe’s resilience to future health crises?   A Continent at Risk The COVID-19 pandemic exposed serious vulnerabilities in the European medicine supply chain. EU countries suddenly found themselves competing for limited supplies of sedatives and antibiotics for ICU care,…

Saudi Arabia Daniel Vella Friggieri, Regional CEO for Europe and the Middle East at Aspen Pharmacare, discusses the company’s growth trajectory over the past 18 months, highlighting the decision to merge the Middle East and European regions into one unit. He reflects on Aspen’s evolving approach in Saudi Arabia, covering localization, talent…

MEA Mohammad El Khoury, General Manager of GE HealthCare in Saudi Arabia, explores the company’s evolution—from adopting direct distribution models to pioneering AI-powered diagnostics—while aligning with Vision 2030. By forging strategic public–private partnerships, enhancing training programs, and fostering a culture of accountability and innovation, GE HealthCare is contributing to reshape the…

Asia A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean biotech getting a 187 million dollar funding boost, why the Australian regulator has rejected Eisai’s Alzheimer’s drug, the activist fund…

Pharma Legal Handbook 1. What are the regulatory authorities with jurisdiction over drugs, biologicals, and medical devices in your country? The regulatory authorities competent in these fields are: the Ministry of Health (http://www.ms.ro/); the National Agency for Medicines and Medical Devices (https://www.anm.ro/); and the National Health Insurance House (http://www.cnas.ro/).   2. What is…

Pharma Legal Handbook 1. Are clinical trials required to be conducted locally as a condition (stated or implicit) for marketing approval? The Romanian law does not expressly provide such limitation as to the performing of clinical trials solely in Romania in view of obtaining the marketing authorization for a certain medicinal product.  …